Cargando…

In Vitro Downregulation of Matrix Metalloproteinase-9 in Rat Glial Cells by CCR5 Antagonist Maraviroc: Therapeutic Implication for HIV Brain Infection

BACKGROUND: Matrix metalloproteinases (MMPs) released by glial cells are important mediators of neuroinflammation and neurologic damage in HIV infection. The use of antiretroviral drugs able to combat the detrimental effect of chronic inflammation and target the exaggerated MMP activity might repres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gramegna, Pasqua, Latronico, Tiziana, Branà, Maria Teresa, Di Bari, Gaetano, Mengoni, Fabio, Belvisi, Valeria, Mascellino, Maria T., Lichtner, Miriam, Vullo, Vincenzo, Mastroianni, Claudio M., Liuzzi, Grazia M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234279/ https://www.ncbi.nlm.nih.gov/pubmed/22174822 http://dx.doi.org/10.1371/journal.pone.0028499

Ejemplares similares

Liver Fibrosis in HCV Monoinfected and HIV/HCV Coinfected Patients: Dysregulation of Matrix Metalloproteinases (MMPs) and Their Tissue Inhibitors TIMPs and Effect of HCV Protease Inhibitors
por: Latronico, Tiziana, et al.
Publicado: (2016)

Inhibition of Myelin-Cleaving Poteolytic Activities by Interferon-Beta in Rat Astrocyte Cultures. Comparative Analysis between Gelatinases and Calpain-II
por: Latronico, Tiziana, et al.
Publicado: (2013)

Maraviroc – A CCR5 Antagonist for the Treatment of HIV-1 Infection
por: Van Der Ryst, Elna
Publicado: (2015)

Longitudinal Assessment of Multiple Immunological and Inflammatory Parameters during Successful DAA Therapy in HCV Monoinfected and HIV/HCV Coinfected Subjects
por: Zuccalà, Paola, et al.
Publicado: (2022)

New approaches in the treatment of HIV/AIDS – focus on maraviroc and other CCR5 antagonists
por: Schlecht, Hans P, et al.
Publicado: (2008)

Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
por: Lorenzen, Thore
Publicado: (2010)

Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model
por: Ochoa-Callejero, Laura, et al.
Publicado: (2013)

The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1
por: López-Huertas, María Rosa, et al.
Publicado: (2017)

Tissue Inhibitor of Matrix Metalloproteinases-1 (TIMP-1) and Pulmonary Involvement in COVID-19 Pneumonia
por: Zingaropoli, Maria Antonella, et al.
Publicado: (2023)

The CCR5 antagonist maraviroc exerts limited neuroprotection without improving neurofunctional outcome in experimental pneumococcal meningitis
por: Le, Ngoc Dung, et al.
Publicado: (2022)

A CCR5 antagonist, maraviroc, alleviates neural circuit dysfunction and behavioral disorders induced by prenatal valproate exposure
por: Ishihara, Yasuhiro, et al.
Publicado: (2022)

Multifunctional Analysis of CD4(+) T-Cell Response as Immune-Based Model for Tuberculosis Detection
por: Lichtner, Miriam, et al.
Publicado: (2015)

Defective production of interferon-γ and tumour necrosis factor-α by AIDS mononuclear cells after in vitro exposure to Rhodococcus equi
por: Delia, S., et al.
Publicado: (1995)

CCR5 Antagonist Maraviroc Inhibits Acute Exacerbation of Lung Inflammation Triggered by Influenza Virus in Cigarette Smoke-Exposed Mice
por: Ferrero, Maximiliano Ruben, et al.
Publicado: (2021)

Hippocampal CCR5/RANTES Elevations in a Rodent Model of Post-Traumatic Stress Disorder: Maraviroc (a CCR5 Antagonist) Increases Corticosterone Levels and Enhances Fear Memory Consolidation
por: Merino, José Joaquín, et al.
Publicado: (2020)

Luminescent PLGA Nanoparticles for Delivery of Darunavir to the Brain and Inhibition of Matrix Metalloproteinase-9, a Relevant Therapeutic Target of HIV-Associated Neurological Disorders
por: Latronico, Tiziana, et al.
Publicado: (2021)

HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry
por: Roche, Michael, et al.
Publicado: (2011)

A Topical Microbicide Gel Formulation of CCR5 Antagonist Maraviroc Prevents HIV-1 Vaginal Transmission in Humanized RAG-hu Mice
por: Neff, C. Preston, et al.
Publicado: (2011)

CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth
por: Casagrande, Naike, et al.
Publicado: (2019)

Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases
por: Sauzullo, Ilaria, et al.
Publicado: (2018)

Inhibitory Effect of Aqueous Extracts from Marine Sponges on the Activity and Expression of Gelatinases A (MMP-2) and B (MMP-9) in Rat Astrocyte Cultures
por: Di Bari, Gaetano, et al.
Publicado: (2015)

In classical Hodgkin lymphoma the combination of the CCR5 antagonist maraviroc with trabectedin synergizes, enhances DNA damage and decreases three-dimensional tumor-stroma heterospheroid viability
por: Casagrande, Naike, et al.
Publicado: (2021)

Antioxidant Compounds from Edible Mushrooms as Potential Candidates for Treating Age-Related Neurodegenerative Diseases
por: Liuzzi, Grazia Maria, et al.
Publicado: (2023)

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations
por: Roche, Michael, et al.
Publicado: (2013)

Dynamic changes of MMP-9 plasma levels correlate with JCV reactivation and immune activation in natalizumab-treated multiple sclerosis patients
por: Iannetta, Marco, et al.
Publicado: (2019)

Stochastic Model of In-Vivo X4 Emergence during HIV Infection: Implications for the CCR5 Inhibitor Maraviroc
por: Savkovic, Borislav, et al.
Publicado: (2012)

Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1
por: Giaquinto, Carlo, et al.
Publicado: (2018)

A randomized controlled clinical trial on the impact of CCR5 blockade with maraviroc in early infection on T-cell dynamics
por: Karris, Maile Y., et al.
Publicado: (2016)

Role of Tocilizumab in Down Regulating sCD163 Plasmatic Levels in a Cohort of COVID-19 Patients
por: Marocco, Raffaella, et al.
Publicado: (2022)

Neuroprotective potential of isothiocyanates in an in vitro model of neuroinflammation
por: Latronico, Tiziana, et al.
Publicado: (2020)

Edible Mushrooms as Source of Fibrin(ogen)olytic Enzymes: Comparison between Four Cultivated Species
por: Petraglia, Tania, et al.
Publicado: (2022)

Antioxidant Activity of Polysaccharides from the Edible Mushroom Pleurotus eryngii
por: Petraglia, Tania, et al.
Publicado: (2023)

Immunological diagnosis as an adjunctive tool for an early diagnosis of tuberculous meningitis of an immune competent child in a low tuberculosis endemic country: a case report
por: Vita, Serena, et al.
Publicado: (2017)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

Severe and Persistent Depletion of Circulating Plasmacytoid Dendritic Cells in Patients with 2009 Pandemic H1N1 Infection
por: Lichtner, Miriam, et al.
Publicado: (2011)

Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon
por: Mascia, Claudia, et al.
Publicado: (2017)

Biomarkers of Neurological Damage: From Acute Stage to Post-Acute Sequelae of COVID-19
por: Zingaropoli, Maria Antonella, et al.
Publicado: (2023)

Role of Double-Carbapenem Regimen in the Treatment of Infections due to Carbapenemase Producing Carbapenem-Resistant Enterobacteriaceae: A Single-Center, Observational Study
por: Cancelli, F., et al.
Publicado: (2018)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

Molecular Mechanisms of Liver Fibrosis in HIV/HCV Coinfection
por: Mastroianni, Claudio M., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_bsjp1o0gdeof5h3fnal8lveroi